Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Sionna Therapeutics (SION), which is developing drugs to treat cystic fibrosis, has filed to raise $100M through an initial public offering. While Sionna (SION) didn't disclose terms in its SEC filing ...

Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Kerry and Munster kingpins Dr Crokes will be well aware of the threat of Tyrone sharpshooters Ruairí and Darragh Canavan ...

Sionna Therapeutics and Odyssey Therapeutics on Friday joined a queue of young developers to publicly reveal IPO plans this ...

She serves as a member of the board of directors of Sionna Therapeutics, PMV Pharmaceutical and Spyre Therapeutics. Laurie received her B.S. in Accounting from Arizona State University and her M.B.A.

RyCarma Therapeutics named Adam Rosenberg, former CEO of Aliada Therapeutics and Sionna Therapeutics, as its CEO. It also hired Jonathan Alspaugh as president and chief strategy officer and Sanjay ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...